



Biotech Daily

Tuesday November 21, 2017

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH EVEN: COMPUMEDICS UP 11%; FACTOR DOWN 6%**
- * **STARPHARMA FILES 'ROLLING' VIVAGEL BV US NDA**
- * **US PATENT FOR EVADO CLINICAL TRIALS MANAGEMENT SOFTWARE**
- * **AUSCANN REQUESTS 'CHILEAN JOINT VENTURE' TRADING HALT**
- * **IMUGENE REQUESTS CAPITAL RAISING TRADING HALT**
- * **ZELDA REQUESTS 'ASX PRICE QUERY' TRADING HALT**
- * **RECCE LOSES 2nd STRIKE VOTE, SPILL MOTION**
- * **STEMCELL PLEADS SCHULTZ TO ASX 59% QUERY; ASX MISSES 16%**
- * **ONE FUNDS DILUTED TO 7.5% OF AVITA**
- * **DIRECTOR SIMON PANTON, SOUTHAM TAKE 17% OF RESONANCE**
- * **NOXOPHARM SHARE TRANSFER ESTABLISHES NYRADA**
- * **PHYLOGICA FOUNDER PROF PAUL WATT RETIRES AS DIRECTOR**
- * **HYDROPONICS APPOINTS DEBBIE ORMSBY CCO**

MARKET REPORT

The Australian stock market was up 0.3 percent on Tuesday November 21, 2017, with the ASX200 up 17.8 points to 5,963.5 points. Fifteen of the Biotech Daily Top 40 stocks were up, 14 fell, eight traded unchanged and three were untraded. All three Big Caps were up.

Compumedics was the best, up four cents or 11.3 percent to 39.5 cents with 171,076 shares traded. Living Cell climbed 6.1 percent; Benitec and LBT improved more than five percent; Avita and Polynovo were up four percent or more; Acrux and Admedus were up more than three percent; Bionomics, Cyclopharm, Opthea, Prana and Universal Biosensors rose more than one percent; with Clinuvel, Cochlear, CSL, Resmed and Viralytics up by less than one percent.

Factor Therapeutics led the falls, down 0.3 cents or 5.7 percent to five cents, with 980,326 shares traded. Actinogen and Orthocell lost more than five percent; Impedimed and Prima fell more than four percent; Dimerix, Medical Developments and Nanosonics shed more than two percent; Ellex, Osprey, Sirtex and Volpara were down one percent or more; with Mesoblast and Starpharma down by less than one percent.

STARPHARMA

Starpharma says it has lodged a “rolling” US Food and Drug Administration new drug application for Vivagel BV for treatment and prevention of bacterial vaginosis.

Starpharma said that Vivagel BV had fast track and qualified infectious disease product designation, which allowed for the rolling submission and ensured priority review.

The company said the application included data from the phase III trials for recurrent bacterial vaginosis, as well as earlier trial data (BD: Aug 7, 2017)

Starpharma said the application comprised five main data modules and this submission included three of the five main modules, with further modules being finalized to be submitted “in the near future” and the FDA review expected to take up to eight months.

Starpharma said it was engaged in negotiations for commercial rights to Vivagel BV, with a number of term sheets under discussion.

Starpharma chief executive officer Dr Jackie Fairley said that her company was “one of very few Australian companies to have achieved an NDA submission”.

“It is very satisfying ... that we have retained the commercial rights to Vivagel BV, while developing the product from discovery through to the successful phase III trials and NDA submission,” Dr Fairley said. “In doing so we’ve maximized its commercial value”.

Starpharma fell half a cent or 0.35 percent to \$1.425.

EVADO

The Melbourne-based Evado says it has been issued its first US Patent for its clinical trials management software system.

Evado said that the patent, entitled ‘A Method and Structure for Managing Multiple Electronic Forms and Their Records Using a Static Database’ protected its intellectual property over the invention by Evado chief architect Ross Anderson until October 16, 2032, with a potential 240 day extension.

The company said the invention enabled “a relational database using a static table structure to store a huge number of form layouts that can all be versioned online”.

Evado said that “millions of form field data instances can be collected for each version of each form” and users could view collections of form data consisting of multiple forms layouts regardless of version and all form field data was directly accessible using a standard SQL statement.

“The USPTO is narrowing the scope for software patents, so we are really thrilled that this patent has been granted,” Mr Anderson said.

Evado is a private company.

AUSCANN GROUP

Auscann has requested a trading halt “pending [the] release of an announcement regarding the company’s Chilean joint venture”.

Trading will resume on November 23, 2017 or on an earlier announcement.

Auscann last traded at 74 cents.

IMUGENE

Imugene has requested a trading halt “pending an announcement in relation to a proposed capital raising”.

Trading will resume on November 23, 2017 or on an earlier announcement.

Imugene last traded at 2.3 cents.

ZELDA THERAPEUTICS

Zelda has requested a trading halt “pending the response to an ASX price query”. Trading will resume on November 23, 2017 or on an earlier announcement.

Zelda last traded up 2.1 cents or 23.6 percent to 11 cents with 22.3 million shares traded.

RECCE

Recce says its annual general meeting voted for a remuneration report second strike and passed the contingent board spill motion.

Recce said that 4,035,644 votes (50.93%) approved the board spill with 3,887,681 votes (49.07%) against, with the remuneration report passed with 4,523,016 votes (56.78%) in favor and 3,443,309 votes (43.22%) against.

The Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 provides for a ‘two strikes and re-election’ process if a company’s remuneration report is opposed by more than 25 percent of votes on two consecutive occasions, taking the company to a board spill vote and if passed by more than 50 percent of votes, the directors must stand for reelection at a subsequent meeting within 90 days. All other resolutions passed by wider margins.

Recce’s most recent Appendix 3B new issue announcement said it had 43,338,794 shares on issue, meaning that the largest dissenting vote, 4,035,644 votes, amounted to 9.3 percent of the company, sufficient to requisition extraordinary general meetings.

Recce was up one cent or 5.4 percent to 19.5 cents.

STEMCELL UNITED

Stemcell has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company’s share price rose 58.8 percent from 3.4 cents on November 20 to 5.4 cents today, November 21, 2017, and noted a significant increase in volume.

Stemcell said it recently announced a \$2.3 million capital raising (BD: Nov 16, 2017).

Stemcell closed up three cents or 75 percent to seven cents with 34.1 million shares traded.

AVITA MEDICAL

The Sydney-based One Funds Management says its 78,347,669 shareholding in Avita has been diluted in the recent capital raising from 10.12 percent to 7.46 percent.

The One Funds Asia-Pacific Healthcare Fund II said it acquired 22,222,222 shares for \$1,000,000 or 4.5 cents a share in a placement that raised \$4.5 million, which was followed by a rights issue which raised a further \$12.4 million (BD: Oct 11, Nov 7, 2017).

Avita was up 0.2 cents or four percent to 5.2 cents.

RESONANCE HEALTH

Resonance director Simon Panton says he has increased his substantial holding in the company from 67,966,163 shares (16.88%) to 68,725,438 shares (17.07%).

The Perth-based Mr Panton said that through Southam Investments 2003 he bought 759,275 shares on market on November 17, 2017 for \$16,584 or 2.2 cents a share.

The substantial shareholder notice said that the Design Council was a co-holder.

Resonance fell 0.2 cents or 8.7 percent to 2.1 cents.

[NOXOPHARM](#)

Noxopharm says it and director Dr Ian Dixon's Altnia Holdings have transferred the shares to establish its US subsidiary Nyrada Inc

Noxopharm said it formed Nyrada as a non-oncology drug development business and following the share transfer Nyrada owned the intellectual property to three non-oncology drug programs (BD: Sep 25, 2017) .

Noxopharm chief executive officer Dr Graham Kelly said Nyrada would "allow Noxopharm to focus its resources on its core aim of bringing NOX66 to market as a major new oncology drug, an opportunity in my view so substantial that it requires clear focus ... [and] provide a means of developing valuable intellectual property that otherwise would risk being side-lined by the need to focus on NOX66".

"Noxopharm shareholders now have a two-thirds stake in a company that I am confident has a strong future as a drug developer," Dr Kelly said.

Noxopharm fell two cents or 2.35 percent to 83 cents.

[PHYLOGICA](#)

Phylogica says that founder Prof Paul Watt will retire as a director and join the scientific advisory board.

Phylogica said that Prof Watt would not stand for re-election at the annual general meeting "to focus on his commitments as director of research services and innovation at the Telethon Kids Institute".

The company said that Prof Watt would also continue to provide services as requested by chief scientific officer Dr Robert Hayes under an existing agreement.

Phylogica said it was "very grateful to Prof Watt for the considerable services he has provided the company as both an executive and more recently director of the board since the company's formation".

"This appointment provides continuity of corporate knowledge and support in the development of the novel biologics platform the company is commercializing," Phylogica said.

Phylogica fell 0.1 cents or 2.6 percent to 3.8 cents with 1.1 million shares traded.

[THE HYDROPONICS COMPANY](#)

Hydroponics says it has appointed Debbie Ormsby as its chief commercial officer, effective from today.

Hydroponics said that Ms Ormsby had pharmaceutical and biotech expertise with experience in product commercialization.

The company said that previously Ms Ormsby was Meda Pharmaceuticals managing-director, the Medicines Company general-manager, Actelion Pharmaceuticals regional medical director, and global study leader at both Roche Products and the Wellcome Foundation.

Hydroponics said that Ms Ormsby held a Bachelor of Pharmacy from England's University of Nottingham.

The company said that last year Ms Ormsby was a consultant assessing the medicinal cannabis market and provided advice which supported Victoria's medicinal cannabis laws.

Hydroponics was up seven cents or 7.4 percent to \$1.02 with 2.1 million shares traded.

**Biotech Daily can be contacted at: [PO Box 5000, Carlton, Victoria, Australia, 3053](mailto:editor@biotechdaily.com.au)
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: [@biotech_daily](https://twitter.com/biotech_daily)**